New Chronic Urticaria Drug Moves to Phase 2 Trial
The FDA approved a new study for the drug VT-7208, which could eventually offer a new treatment option for adults with chronic hives.
Updated on Oct. 29, 2026 in Allergies

Live Poll
Do you consider the expansion of clinical-stage pharmaceutical companies a positive sign for future medical treatment options?
The FDA has cleared an investigational new drug application to begin a Phase 2 trial of VT-7208 for adults with chronic spontaneous urticaria. This study will evaluate the treatment in approximately 120 patients to address a condition that affects up to 2 million U.S. adults.
Why it matters
Processa Pharmaceuticals is developing this drug to provide a therapeutic alternative to current injectable FcRn therapies for patients with this persistent skin condition. The trial seeks to expand treatment options for a large population currently managing this diagnosis.
The planned Phase 2 study will enroll 120 adults with moderate-to-severe disease to compare the drug against a placebo over a 12-week period. As a new investigational drug trial, findings regarding the safety and clinical effectiveness of the treatment remain currently unknown.
The players
Processa Pharmaceuticals
A pharmaceutical company headquartered in Vero Beach, Florida, that focuses on building an immunology-driven drug pipeline.
Sheila Gujrathi
The newly appointed Executive Chair of the Board of Directors at Processa Pharmaceuticals who previously served on the board.
Generian Pharmaceuticals
A research entity that has entered into a collaboration and exclusive option agreement with Processa Pharmaceuticals.
The details
VT-7208 is being developed as an alternative to existing injectable FcRn therapies, which are used to modulate immune responses. The upcoming multicenter, double-blind study is designed to measure how the drug performs in adults over the course of 12 weeks of treatment. By targeting the immune system, the drug aims to offer a different mechanism of action for those struggling with the symptoms of chronic spontaneous urticaria.
Timeline
October 29, 2026: FDA clearance for the VT-7208 investigational study was announced.
June 2026: Processa Pharmaceuticals acquired Vidya Therapeutics.
Second half of 2029: Company cash resources are projected to support operations until this time.
Health Landscape
The development of VT-7208 represents an effort to challenge the current standard of care dominated by injectable FcRn therapies. It sits among a growing number of emerging immunological treatments aiming to provide alternatives for patients with chronic autoimmune and allergic conditions.
This development is an early-stage research finding and does not change your current treatment plan or medication access today. Patients living with chronic spontaneous urticaria should continue to discuss symptom management and new therapeutic developments with their primary care physician or allergist.
The takeaway
While this trial offers a potential new avenue for treating chronic spontaneous urticaria, it remains in the early stages of human testing. If you are managing this condition, keep a record of your symptoms and potential triggers to review during your next conversation with a physician.
Further reading
For more information on managing skin-related immune conditions, explore our Allergies section.
Source note: This article includes information reported by The Manila times.
Live Poll
Do you consider the expansion of clinical-stage pharmaceutical companies a positive sign for future medical treatment options?





